Achieve Life Sciences, Inc. (ACHV): Depreciation & Amortization

Annual figures by period end, from SEC filings.

$228.0K
Year ended 2025-12-31
$226.0K
Trailing 12 months to 2026-06-30
-1.1%
3-year compound annual growth
-2.2%
5-year compound annual growth
$255.0K2020-12-31: $255.0K2021-12-31: $250.0K2022-12-31: $236.0K2023-12-31: $228.0K2024-12-31: $229.0K2025-12-31: $228.0K$228.0K
2020-12-31 Depreciation & Amortization (USD) 2025-12-31
Period endedDepreciation & AmortizationChange YoYSource filing
2025-12-31$228.0K-0.4%2026-03-24, From 2025-01-01
2024-12-31$229.0K+0.4%2026-03-24, From 2024-01-01
2023-12-31$228.0K-3.4%2026-03-24, From 2023-01-01
2022-12-31$236.0K-5.6%2025-03-11, From 2022-01-01
2021-12-31$250.0K-2.0%2024-03-28, From 2021-01-01
2020-12-31$255.0Kn/a2023-03-16, From 2020-01-01

Depreciation & Amortization at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedDepreciation & AmortizationChange YoY
Achieve Life Sciences, Inc. (ACHV)2025-12-31$228.0K-0.4%
Immucell Corp (ICCC)2025-12-31$2.78M+2.0%
Insight Molecular Diagnostics Inc. (IMDX)2025-12-31$2.19M+48.4%
Alpha Teknova, Inc. (TKNO)2025-12-31$6.34M-3.6%
Cardio Diagnostics Holdings, Inc. (CDIO)2025-12-31$65.2K+230.5%
Volitionrx Ltd (VNRX)2025-12-31$983.7K-11.6%
Biomerica Inc (BMRA)2026-05-31$77.0K-11.5%
Aspira Women's Health Inc. (AWHL)2025-12-31$112.0K+21.7%
Celldex Therapeutics, Inc. (CLDX)2025-12-31$3.38M+6.4%

Compare ACHV, ICCC, IMDX, TKNO side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗